October 2020

Handling COVID biomedical waste critical to prevent future epidemics – Express Healthcare

Read Article In the run up to World Ecology Day (November 1), Satyendra Johari, Founder & Chairman, Johari Digital Healthcare warns that the rise in biomedical waste due to the COVID pandemic has led to an immediate threat of unsafe disposal of healthcare waste that will pollute the environment as well as pose a risk

Handling COVID biomedical waste critical to prevent future epidemics – Express Healthcare Read More »

Delhi: 60% ventilator beds full, but good recovery rate a boost – ET HealthWorld

Representative image New Delhi: Covid-19 bed occupancy and ventilator requirement in Delhi government and private hospitals have witnessed a sharp rise in the past fortnight. With the number of daily new cases rising due to multiple factors, including season change, high pollution and reckless behaviour by citizens, nearly 40% of the Covid beds and 60%

Delhi: 60% ventilator beds full, but good recovery rate a boost – ET HealthWorld Read More »

Gilead’s Covid drug is mediocre. It will be a blockbuster anyway. – ET HealthWorld

By Katie Thomas The United States reached a milestone, of sorts, when last week the Food and Drug Administration approved the first treatment for Covid-19. The drug is called Veklury, although most people know it by its scientific name, remdesivir. On Wednesday, its manufacturer, Gilead Sciences, said that remdesivir, which has been authorized for emergency

Gilead’s Covid drug is mediocre. It will be a blockbuster anyway. – ET HealthWorld Read More »

FDC launches stronger versions of its generic Covid drug, Favipiravir, in India – ET HealthWorld

New Delhi: Drug firm FDC Ltd on Friday said it has launched stronger versions of its Favipiravir brands, PiFLU and Favenza, used to treat mild-to-moderate cases of COVID-19, at a price of Rs 160 per tablet in India. These prescription-only drugs will be available at all retail medical outlets and hospital pharmacies across the country,

FDC launches stronger versions of its generic Covid drug, Favipiravir, in India – ET HealthWorld Read More »

Acadia premieres medical adaptation of Williams documentary

Actor Robin Williams struggled with Lewy body dementia near the end of his life, but he didn’t know it. The famous funnyman’s experience isn’t that different from those of many people with the condition—it’s the second most common, but also most misdiagnosed, type of dementia. To help the medical community better understand the disease, Acadia

Acadia premieres medical adaptation of Williams documentary Read More »

Down to the Atoms

I wanted to mention something that was reported a week or so ago, and may sound a bit exotic or obscure, if you’re not a structural biologist. But it’s yet another sign of a revolution in our ability to get structures of biomolecules (and others) that we never would have before, and the effects over

Down to the Atoms Read More »

AbbVie pegs growth to booming Skyrizi, Rinvoq in post-merger future. But neurology could be a ‘sleeper’

With its $63 billion merger with Allergan in the rearview, the new AbbVie is facing a major challenge as U.S. biosimilars for Humira cast a pall over the near-term future. But AbbVie figures its homegrown prospects will keep driving growth—and a couple of surprises from Allergan could make the forecast even rosier.  After six months

AbbVie pegs growth to booming Skyrizi, Rinvoq in post-merger future. But neurology could be a ‘sleeper’ Read More »

Scroll to Top